Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma

被引:0
作者
Gabriele Carlinfante
Daphne Vassiliou
Olle Svensson
Mikael Wendel
Dick Heinegård
Göran Andersson
机构
[1] Huddinge University Hospital,Division of Pathology/ IMPI, Karolinska Institute, and Clinical Research Centre
[2] Istituti Ospitalieridi Cremona,Division of Pathology
[3] Huddinge University Hospital,Division of Pathology/ IMPI, Karolinska Institute, and Clinical Research Centre
[4] Umeá University,Division of Orthopaedics
[5] Karolinska Institute,The Centre of Oral Biology, Novum Research Centre
[6] Lund University,Department of Cell
来源
Clinical & Experimental Metastasis | 2003年 / 20卷
关键词
bone metastasis; bone sialoprotein; osteopontin;
D O I
暂无
中图分类号
学科分类号
摘要
Breast and prostate cancer often metastasise to the skeleton. Interestingly, the histopathological characteristics of the bone lesions that arise from these two cancer types differ. Breast tumours give rise to metastases in the skeleton with a mixed lytic/sclerotic pattern, whereas a predominantly sclerotic pattern is seen in metastases from prostate tumours. Osteopontin (OPN) and bone sialoprotein (BSP) are bone matrix proteins that have been implicated in the selective affinity of cancer cells for bone. In the present study, 21 patient cases with skeletal metastasis and their respective primary tumours (12 with breast cancer, 9 with prostate cancer) were investigated by immunohistochemistry in order to assess the level of OPN and BSP. Moderate to strong OPN expression was found in 42% of all breast tumours and in 56% of all prostate tumours. Significantly more breast cancer bone metastases exhibited high OPN expression, 83%, as compared with prostate tumour bone metastases, 11% (P=0.0019). In contrast, moderate to strong BSP expression was found in 33% of breast tumours and in 89% of prostate tumours. In the bone lesions, only 33% of breast tumour metastases showed moderate/strong BSP expression compared to 100% of prostate tumour metastases (P=0.0046). This divergent pattern of OPN/BSP expression could be an important determinant for the different characteristics of these two types of bone metastasis, i.e., lytic vs. sclerotic, consistent with the proposed role of OPN in differentiation and activation of osteoclasts and of BSP as a stimulator of bone mineralisation.
引用
收藏
页码:437 / 444
页数:7
相关论文
共 143 条
[1]  
Mundy GR(1997)Mechanisms of bone metastasis Cancer 80 1546-56
[2]  
Giachelli CM(2000)Osteopontin: A versatile regulator of inflammation and biomineralization Matrix Biol 19 615-22
[3]  
Steitz S(2000)Osteopontin Crit Rev Oral Biol Med 11 279-303
[4]  
Sodek J(1995)Roles of osteopontin in bone remodeling Ann NY Acad Sci 760 213-22
[5]  
Ganss B(1992)Expression and distribution of osteopontin in human tissues: Widespread association with luminal epithelial surfaces Mol Biol Cell 3 1169-80
[6]  
McKee MD(1997)The role of osteopontin in tumorigenesis and metastasis Invasion Metastasis 17 1-15
[7]  
Heinegard D(1997)Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival Clin Cancer Res 3 605-11
[8]  
Andersson G(1998)The LCC15—MB human breast cancer cell line expresses osteopontin and exhibits an invasive and metastatic phenotype Exp Cell Res 241 273-84
[9]  
Reinholt FP(1998)Osteopontin expression in a group of lymph node negative breast cancer patients Internl J Cancer 79 502-8
[10]  
Brown LF(1996)The identification of osteopontin as a metastasis—related gene product in a rodent mammary tumour model Oncogene 13 97-104